A secondary post hoc analysis of patients who had neovascular age-related macular degeneration (AMD) and were treated with intravitreal aflibercept or ranibizumab—2 widely used anti-vascular endothelial growth factor (anti-VEGF) therapies—found that those with certain characteristics had a substantial risk of conversion to AMD in the untreated eye.
A secondary post hoc analysis of patients who had neovascular age-related macular degeneration (AMD) and were treated with intravitreal aflibercept or ranibizumab—2 widely used anti-vascular endothelial growth factor (anti-VEGF) therapies—found that those with certain characteristics had a substantial risk of conversion to AMD in the untreated eye.
The study, published in Thursday in JAMA Ophthalmology, aimed to assess the association of the anti-VEGF medication and dosing regimen with the incidence of conversion to AMD in the other eye of patients treated with ranibizumab or intravitreal aflibercept injection (IAI). The study also sought to identify baseline characteristics influencing the incidence of conversion.
Researchers used randomized clinical trial data from the Vascular Endothelial Growth Factor Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) studies. The VIEW 1 and VIEW 2 studies were randomized, double-masked, active-controlled, multicenter, 96-week, phase 3 trials of IAI in 2457 patients with neovascular AMD who had not yet been treated.
The current study analyzed a subgroup of participants (n = 1561) treated for neovascular AMD in 1 eye who had untreated fellow eyes without neovascularization at baseline.
All participants in the prior studies were included in 1 of 4 groups: ranibizumab, 0.5mg, every 4 weeks; aflibercept, 2mg, every 4 weeks; aflibercept, 0.5mg, every 4 weeks; or aflibercept, 2mg, every 8 weeks after 3 injections at 4-week intervals.
The incidence of fellow eye conversion was 26.2% to 32.2% across treatment groups through week 96, and there was no difference in conversion rates across treatment groups. Patients received no treatment in the fellow eyes unless they had conversion to neovascular AMD.
Factors associated with higher risk of fellow eye conversion were increasing age, female sex, baseline intraretinal fluid in the study eye, and increasing choroidal neovascularization lesion size in the study eye.
Patients at high risk for conversion should be monitored closely, the researchers wrote.
At 96 weeks, 375 patients (24.0%) experienced cases of conversion to neovascular disease in the fellow eye, including:
The rates of conversion were 18.1, 16.2, 14.7, and 16.0 per 100 patient-years at risk at week 96, respectively.
On multivariate analysis, fellow eye conversion was associated with increasing patient age (per 10 years) at baseline (hazard ratio [HR], 1.20; 95%CI, 1.05-1.36), female sex (HR, 1.32; 95% CI, 1.06-1.63), intraretinal fluid in the study eye at baseline (HR, 1.28; 95% CI, 1.02-1.61), and increasing choroidal neovascularization lesion size (per 10mm2) in the study eye at baseline (HR, 1.29; 95% CI, 1.06-1.57).
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.